Linnaeus Therapeutics, co-founded in 2016 by Todd Ridky, MD, PhD, Associate Professor of Dermatology at Penn Medicine, and Christopher Natale, PhD, a prior graduate student in the Ridky Lab, will use these funds to further develop LNS880, an oral, first-in-class drug that selectively activates the G protein-coupled estrogen receptor (GPER). The funded program will assess whether LNS880 can preserve physical and cognitive function, improve cardiometabolic health, delay age-related decline and even improve survival in patients with cancer. Read more here.